Profile data is unavailable for this security.
About the company
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
- Revenue in USD (TTM)3.21m
- Net income in USD-73.22m
- Incorporated2007
- Employees6.00
- LocationSynlogic Inc301 Binney St Ste 402CAMBRIDGE 02142-1030United StatesUSA
- Phone+1 (617) 401-9975
- Fax+1 (302) 636-5454
- Websitehttps://www.synlogictx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aytu Biopharma Inc | 93.76m | -13.68m | 17.82m | 150.00 | -- | 0.5789 | -- | 0.19 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 124.00k | -14.69m | 17.99m | 49.00 | -- | -- | -- | 145.10 | -56.83 | -56.83 | 0.0902 | -- | -- | -- | -- | 2,530.61 | -- | -100.11 | -- | -131.65 | -- | -- | -11,846.77 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 18.34m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
| Trinity Biotech plc (ADR) | 56.71m | -33.88m | 18.93m | 380.00 | -- | -- | -- | 0.3338 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Synlogic Inc | 3.21m | -73.22m | 18.97m | 6.00 | -- | 1.41 | -- | 5.92 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 19.07m | 33.00 | -- | 1.09 | -- | 12.51 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 19.19m | 46.00 | 0.7337 | 0.376 | 0.7238 | 0.2875 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Jaguar Health Inc | 10.14m | -38.32m | 19.19m | 49.00 | -- | 1.49 | -- | 1.89 | -78.63 | -78.63 | 9.90 | 3.18 | 0.1806 | 0.2397 | 8.12 | 206,938.80 | -69.22 | -95.29 | -122.86 | -163.54 | 79.07 | 67.28 | -383.35 | -522.28 | 1.39 | -2.78 | 0.6919 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -39.55m | 19.24m | 43.00 | -- | 2.89 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| AIM ImmunoTech Inc | 193.00k | -31.12m | 19.28m | 26.00 | -- | 4.57 | -- | 99.91 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 19.51m | 109.00 | -- | 0.2517 | -- | 11.61 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 19.65m | 40.00 | -- | 3.49 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 19.74m | 8.00 | -- | 1.96 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Polypid Ltd | 0.00 | -24.25m | 19.91m | 59.00 | -- | 2.79 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Allied Corp | 21.51k | -9.00m | 20.00m | -- | -- | -- | -- | 929.77 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Synlogic Inc's reporting currency: US Dollar USD
34.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cable Car Capital LLCas of 31 Mar 2024 | 3.31m | 28.44% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 223.66k | 1.92% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 181.93k | 1.56% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 118.44k | 1.02% |
| Geode Capital Management LLCas of 31 Mar 2024 | 47.60k | 0.41% |
| Fiduciary Trust Co.as of 31 Mar 2024 | 22.35k | 0.19% |
| Citadel Securities LLCas of 31 Mar 2024 | 21.17k | 0.18% |
| Ikarian Capital LLCas of 31 Mar 2024 | 20.45k | 0.18% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 19.76k | 0.17% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 10.28k | 0.09% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
